Johnson & Johnson, “effective vaccine on Delta variant”

Johnson & Johnson, Janssen’s single-dose Covid vaccine “demonstrated a durable immune response and generated neutralizing antibody responses against the Delta variant and other Sars-CoV-2 variants of concern.” This was reported by J&J, communicating the interim results of a phase 1 / 2a substudy published in the ‘New England Journal of Medicine’ (Nejm). “Antibody and T-cell immune responses were observed for at least 8 months after immunization,” reports the US pharmaceutical group. Furthermore, “neutralizing antibody activity against the Delta variant (B.1.617.2) has been shown to increase over time”. J&J announced the results of this substudy in a pre-publication on July 1st.